Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16

Pierce, John P.; Benmarhnia, Tarik; Chen, Ruifeng; White, Martha M.; Abrams, David B.; Ambrose, Bridget K.; Blanco, Carlos; Borek, Nicolette; Choi, Kelvin; Coleman, Blair; Compton, Wilson M.; Cummings, K. Michael; Delnevo, Cristine D.; Elton‐Marshall, Tara; Goniewicz, Maciej Ł.; Gravely, Shannon; Fong, Geoffrey T.; Hatsukami, Dorothy K.; Henrie, James; Kasza, Karin A.; Kealey, Sheila; Kimmel, Heather L.; Limpert, Jean; Niaura, Raymond; Ramôa, Carolina; Sharma, Eva; Silveira, Marushka L.; Stanton, Cassandra A.; Steinberg, Michael B.; Taylor, Ethel; Bansal-Travers, Maansi; Trinidad, Dennis R.; Gardner, Lisa; Hyland, Andrew; Soneji, Samir; Messer, Karen

doi:10.1371/journal.pone.0237938

Cited by 50 publications

(54 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most notably, the study provided behavioral support to participants in both arms, which, although best practice, is not used by the majority of people trying to quit smoking (Shiffman et al 2008). The results of this study conflict with earlier findings (Kalkhoran and Glantz 2016), and two more recent U.S. studies using longitudinal survey data from the Population Assessment of Tobacco and Health (PATH) concluded that in realworld settings, those using e-cigarettes to assist in smoking cessation were no more likely to succeed than those using NRT (Chen et al 2020;Pierce et al 2020).…”

Section: Statistic 2: Nearly Twice As Effective As Nrtcontrasting

confidence: 85%

E-Cigarettes and the Multiple Responsibilities of the FDA

Svirsky

Howard

Berman

2021

The American Journal of Bioethics

View full text Add to dashboard Cite

This paper considers the responsibilities of the FDA with regard to disseminating information about the benefits and harms of e-cigarettes. Tobacco harm reduction advocates claim that the FDA has been overcautious and has violated ethical obligations by failing to clearly communicate to the public that e-cigarettes are far less harmful than cigarettes. We argue, by contrast, that the FDA's obligations in this arena are more complex than they may appear at first blush. Though the FDA is accountable for informing the public about the health risks and benefits of products it regulates, it also has other roles (and attendant responsibilities) that inform when and how it should disseminate information. In addition to being a knowledge purveyor, it is also a knowledge producer, an advisor to the public, and a practical agent shaping the material conditions in which people make health-related choices. In our view, those other roles call for caution in the way the FDA interprets and communicates the available evidence.

show abstract

Section: Statistic 2: Nearly Twice As Effective As Nrtcontrasting

confidence: 85%

E-Cigarettes and the Multiple Responsibilities of the FDA

Svirsky

Howard

Berman

2021

The American Journal of Bioethics

View full text Add to dashboard Cite

show abstract

“…A recent publication by Glasser et al 1 reports a series of analyses on the associations of e-cigarette use and cigarette abstinence. Of interest, the two senior authors were also co-authors on another recent publication 2 reporting on e-cigarette use and cigarette abstinence that came to a strikingly different conclusion, despite using the same data set from the Population Assessment of Tobacco and Health (PATH) cohort study.…”

mentioning

confidence: 99%

E-cigarettes and Cessation: The Introduction of Substantial Bias in Analyses of PATH Study

Pierce

Leas

Benmarhnia

et al. 2020

Nicotine &Amp; Tobacco Research

Self Cite

View full text Add to dashboard Cite

“…For instance, one study found that e-cigarettes are effective for smoking cessation in young adults with high nicotine dependence levels ( Selya et al, 2018 ). Two other studies found that e-cigarettes have similar smoking cessation effectiveness to not using any products or using conventional pharmacotherapy after 1–2 years of abstinence ( Weaver et al, 2018 , Pierce et al, 2020 ). A fourth found that hospital patients using e-cigarettes have less success with smoking abstinence compared to non-users after 6 months ( Rigotti et al, 2018 ).…”

Section: Is Vaping a Viable Smoking Cessation Aid?mentioning

confidence: 97%

Smoking cessation or initiation: The paradox of vaping

Al‐Hamdani

Manly

2021

Preventive Medicine Reports

View full text Add to dashboard Cite

Highlights The number of people vaping, especially adolescents, has surged in recent years. Studies of vaping as a smoking cessation tool have been largely inconclusive. Studies have produced compelling evidence linking vaping to smoking initiation . Early vaping studies have revealed numerous detrimental effects on the body.

show abstract

Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16

Abstract: Background More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy. Objective To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use.

Cited by 50 publications

References 36 publications

E-Cigarettes and the Multiple Responsibilities of the FDA

E-Cigarettes and the Multiple Responsibilities of the FDA

E-cigarettes and Cessation: The Introduction of Substantial Bias in Analyses of PATH Study

Smoking cessation or initiation: The paradox of vaping

Contact Info

Product

Resources

About